Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 144

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 144
---
 (Audited).

The following table sets forth key components of the results of operations for fiscal years ended December 31, 2024 and 2023, respectively. 

The discussion following the table addresses these results.

Consolidated Year ended   December 31, (Audited)   2024  2023        REVENUE (including $112,556 and $106,919 of revenue from related parties for the year ended December 31, 2024 and 2023 respectively) $9,510,646  $9,770,806          COST OF REVENUE (including $297,736 and $184,433 of cost of revenue from related parties for the years ended December 31, 2024 and 2023, respectively)  (8,221,125)  (8,441,308)         GROSS PROFIT  1,289,521   1,329,498          OTHER INCOME  2,072,473   486,036          OPERATING EXPENSES        Sales and marketing  (2,030,684)  (596,858)Research and development  (47,511)  (54,982)General and administrative  (1,973,968)  (2,442,855)Provision for expected credit losses   (883,533)  (1,314,427)TOTAL OPERATING EXPENSES  (4,935,696)  (4,409,122)         LOSS FROM OPERATIONS  (1,573,702)  (2,593,588)         FINANCE COSTS  (21,146)  (13,929)         LOSS BEFORE TAX  (1,594,848)  (2,607,517)         Tax expense:        Deferred tax  12,305   17,359 Income tax  (15,799)  (38,885)Tax expense  (3,494)  (21,526)         NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(1,598,342) $(2,629,043)         Other comprehensive income/(loss):        Foreign currency translation gain/(loss)  122,294   (268,232